Результаты :

Rechercher Расширенный поиск


Создать форум

The objective response rate inside the total population was

Предыдущая тема Следующая тема Перейти вниз

The objective response rate inside the total population was

Сообщение  qq123456 в Вт Дек 23, 2014 2:45 pm

Discussion Decitabine treatment was previously connected with im proved outcomes compared with TC in older individuals with AML. This multivariate evaluation of information from a significant, randomized phase 3 trial in older sufferers with newly diagnosed AML demonstrated オーダー Amuvatinib that all subgroups had responses favoring decitabine, even these with poorer prognostic elements, such as baseline bone marrow blasts 30%. Furthermore, steady with identified prognos tic things for older individuals with AML, individuals aged 75 many years and 70 74 many years had worse prognoses compared with sufferers 70 years. Additionally, poorer baseline ECOG PS and ailment related factors, this kind of as poor cytogenetics, higher bone marrow blast counts, lower baseline platelet counts, and higher WBC counts, all pre dicted worse OS.<br><br> Interestingly, neither the kind of AML nor patient intercourse influenced OS. Despite the association among age and poorer prog nosis replicated in these submit hoc analyses, the general trend for treatment method advantage with decitabine was more obviously observed in sufferers aged 70 74 many years and in pa tients 75 many years in contrast with people AT-406 supplier 70 many years. Hazard ratios for OS had been 0. 79 and 0. 72 for sufferers aged 70 74 and 75 years, respectively. Individuals aged 70 many years demonstrated response costs of 16. 9% and median OS of 9. one months, which were con sistent with overall success for decitabine handled sufferers.<br><br> Survival and response results in older sufferers re ported on this trial are especially promising provided that published information indicate that response and survival in clinical trials are normally diminished because the patients age increases. Median survival in this trial was eight. 0 months in sufferers aged 70 74 many オーダー AG-490 years and six. three months in those aged 75 many years, which compares favorably with historical information on this older population. These favorable findings for decitabine in older patients are intriguing and may possibly warrant additional investigation to determine the beneath lying explanation. A retrospective analysis of 968 grownups with AML in 5 Southwest Oncology Group trials re vealed a median OS of six. 9 months in patients aged 66 75 years, but only three. five months in individuals older than 75 many years.<br><br> In the separ ate examination of 998 sufferers aged 65 years with AML or large risk MDS handled with intensive chemotherapy, me dian OS in sufferers aged 75 and older was only 18 weeks compared with 34 weeks in sufferers aged 70 74 many years, and 29 weeks in sufferers aged 65 69 many years. In con trast, much more recent analyses of azacitidine in sufferers with 20% to 30% bone marrow blasts versus traditional care, recommend a survival advantage for azacitidine more than conventional care of 24. five months versus 16. 0 months, respectively, although the atypically higher median OS associated with standard care suggests some patient variety bias. Particularly, patients inside the azacitidine trial had superior prognostic elements than did the substantial possibility patients in the present decitabine trial. Notable during the recent analyses would be the end result for pa tients during the Western European subgroup, who had a longer median OS in contrast with sufferers from other regions. In this little subgroup, median OS while in the TC arm for your major analysis was substantially longer than that in any other area and was associ ated which has a wide self confidence interval.


Количество сообщений : 266
Дата регистрации : 2014-07-17

Посмотреть профиль

Вернуться к началу Перейти вниз

Предыдущая тема Следующая тема Вернуться к началу

Права доступа к этому форуму:
Вы не можете отвечать на сообщения